Stevanato Group Investor Presentation
FY 2023: Financial Highlights
FY 2023 Revenue
(€ Million)
984
Non HVS
HVS
+10%
93
Base
business
Covid-19
headwind
1.085
366
(34%)
+25%
11% revenue growth on a CC basis driven by growth in both segments,
higher volumes and the mix shift to high value solutions.
●
Record revenue from HVS, representing 34% of total revenue
Excluding Covid-19 (estimated to be ~2% of total revenue), revenue
grew 22% yoy
Gross profit margin decline due to lower EZ-FillⓇ vial volumes, temporary
inefficiencies tied to start-up, higher depreciation, FX, and short-term
underutilization on some vial lines
293
(30%)
FY 2022
FY 2023 Margins
Gross Profit Margin
Operating Profit Margin
SG, Stevanato Group
FY 2023
Operating profit decrease due to lower gross profit and other income
On the bottom line:
• Net profit of € 145.7M (+2% yoy), or € 0.55 of diluted EPS
Adjusted net profit¹ of € 154.7M (+5% yoy), or € 0.58 of adjusted diluted
EPS¹
FY 2023
FY 2022
31.3%
32.5%
18.5%
19.6%
Adjusted EBITDA¹ of € 291.5M (+11% yoy); adjusted EBITDA margin¹ of
26.9% (+10 bps yoy)
¹Adjusted operating profit margin, adjusted net profit, adjusted DEPS, adjusted EBITDA and adjusted EBITDA margin, Net Debt, CapEx, Free Cash Flow are non-GAAP financial measures. Please refer to slides 37 to 46 for a
reconciliation of non-GAAP measures.
Stevanato Group Investor Presentation, March 2024
21View entire presentation